Cargando…
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is limited, making the identification of novel therapies for mCRPC critical. We have found that defic...
Autores principales: | Flaig, Thomas W., Salzmann-Sullivan, Maren, Su, Lih-Jen, Zhang, Zhiyong, Joshi, Molishree, Gijón, Miguel A., Kim, Jihye, Arcaroli, John J., Van Bokhoven, Adrie, Lucia, M. Scott, La Rosa, Francisco G., Schlaepfer, Isabel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593544/ https://www.ncbi.nlm.nih.gov/pubmed/28915573 http://dx.doi.org/10.18632/oncotarget.17359 |
Ejemplares similares
-
OR34-4 ATF3 Is A Converging Point For AR Signaling And Fatty Acid Oxidation In Prostate Cancer
por: Joshi, Molishree, et al.
Publicado: (2019) -
CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
por: Joshi, Molishree, et al.
Publicado: (2019) -
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
por: Nordeen, Steven K., et al.
Publicado: (2021) -
Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011) -
CPT1A Over-Expression Increases Reactive Oxygen Species in the Mitochondria and Promotes Antioxidant Defenses in Prostate Cancer
por: Joshi, Molishree, et al.
Publicado: (2020)